Drug firm Lupin is planning to expand its footprint in Latin America. It will preferably acquire companies in Brazil, Mexico, Argentina and Chile and the fund for the acquisition will be raised through internal accruals. The company intends taking both organic and inorganic routes for future growth.
The pharma major has a history of acquiring firms that suit its business plans, last being acquisition of Japan’s speciality injectables company I’rom Pharmaceutical in 2011.
Besides, the Mumbai-based company is targeting to buy brands in key therapeutic areas. In this regard, it is in talks with several companies in the US for the purpose.
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
